GMED Globus Medical Inc Class A

Globus Medical Enters International Market with ExcelsiusGPS® Robotic Guidance and Navigation System

Globus Medical Enters International Market with ExcelsiusGPS® Robotic Guidance and Navigation System

First surgeries performed in Greece, Germany, and Italy

AUDUBON, Pa., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, recently announced the entrance of ExcelsiusGPS®, a revolutionary robotic guidance and navigation system, to the international market with system installations completed in several European countries. This past October, the first European Excelsius GPS® procedure was performed at the Metropolitan Hospital in Neo Faliro, Athens, Greece by Mr. Panagiotis E. Zoumpoulis. Since then, numerous open and minimally invasive spine procedures have been performed at Bonifatius Hospital in Germany and at the Fornaca Clinic in Italy.

“Surgeons and hospital administrators in the United States have shown tremendous levels of interest in ExcelsiusGPS® since it first launched domestically at the end of 2017,” said Dave Demski, Chief Executive Officer at Globus Medical. “Users have realized the system’s ability to help advance patient care and provide tangible benefits for surgeons and their staff. As we begin to scale our efforts abroad, we have seen similar levels of enthusiasm within the international surgeon community and look forward to the continued adoption of ExcelsiusGPS® into these markets.” 

Italy’s first surgeries were performed by Prof. Franco Benech, and Dr. Carlo Alberto Benech, from Benech Neurosurgery and Spine Specialists in Turin, Italy at the Fornaca Clinic. “With the addition of ExcelsiusGPS® we now offer patients seeking spine surgery a level of accuracy that was not possible without this technology,” said Prof. Benech. “Our team is committed to providing the highest level of care to our patients by offering the latest advancements in robotic-assisted spine surgery at our facilities.” 

Professor Peter Douglas Klassen with Bonifatius Hospital in Lingen, Germany echoes a similar sentiment, commenting, “ExcelsiusGPS® is truly a revolutionary technology designed to improve surgeon wellness and patient care. We are excited about the potential impact that robotic guidance and navigation may have in improving screw placement accuracy, MIS efficiency, and reducing radiation exposure.”

About Globus Medical, Inc.

, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at .

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at . Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:

Brian Kearns

Vice President, Business Development and Investor Relations

Phone: (610) 930-1800

Email: 

 

EN
06/12/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Globus Medical Inc Class A

 PRESS RELEASE

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

Globus Medical Reports Fourth Quarter and Full Year 2025 Results AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for ...

 PRESS RELEASE

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Re...

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Parti...

 PRESS RELEASE

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year...

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over ...

Globus Medical Inc: 1 director

A director at Globus Medical Inc sold 4,000 shares at 88.850USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

Globus Medical Reports Third Quarter 2025 Results

Globus Medical Reports Third Quarter 2025 Results AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share (“EP...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch